首页> 美国卫生研究院文献>other >Early and midterm outcomes of thoracic endovascular aortic repair (TEVAR) for acute and chronic complicated type B aortic dissection
【2h】

Early and midterm outcomes of thoracic endovascular aortic repair (TEVAR) for acute and chronic complicated type B aortic dissection

机译:急慢性复杂性B型主动脉夹层的胸腔内血管主动脉修复(TEVAR)的早期和中期结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Thoracic endovascular aortic repair (TEVAR) in the current era has been chosen as a dominant and minimally invasive treatment for complicated aorta dissection. This study aimed to assess safety and feasibility of TEVAR in acute and chronic type B aortic dissection.Between January 2011 and December 2013, 85 patients with complicated type B aortic dissection undergoing TEVAR were divided into acute aortic dissection (AAD) (n = 60) group and chronic aortic dissection (CAD) group (n = 25). Computed tomography was used to evaluate postoperative changes in maximal aortic diameter and true and false lumen diameters at 3 levels during a mean follow-up period of 26.4 ± 15.6 months.The technical success rate was 100%. In-hospital and 30-day rates of death were 3.3% in acute group and 0 in chronic group. Postdischarge rates of type I leak, type II leak, and retrograde type A dissection were 6.7%, 5.2%, and 3.4% (acute) and 0%, 4.0%, and 4.0% (chronic), respectively. The maximal aorta diameter remained stable in all the 3 levels in both acute and chronic group. The cumulative freedom from all-cause mortality at 3 years was similar in acute and chronic groups (89.5% vs 95.5%, P = .308). The cumulative freedom from aortic-related mortality was also not significantly different in the acute and chronic groups (92.8% vs 95.2%, P = .531). In the thoracic aorta, TEVAR treatment resulted in a significant increase in true lumen (TL) diameter and decrease in false lumen (FL). However, in the abdominal aorta, TEVAR did not lead to significant change in TL and FL diameters. The rates of complete thrombosis thoracic false lumens were better than that in the abdominal false lumen.TEVAR was a safe and effect therapy for complicated acute and chronic type B dissection with low early and mid-term mortality and morbidity.
机译:在当前时代,胸腔血管内主动脉修复术(TEVAR)已被选为复杂的主动脉夹层的主要且微创治疗方法。这项研究旨在评估TEVAR在急,慢性B型主动脉夹层中的安全性和可行性.2011年1月至2013年12月,将85例行TEVAR的复杂B型主动脉夹层患者分为急性主动脉夹层(AAD)(n = 60)组和慢性主动脉夹层(CAD)组(n = 25)。在平均随访时间26.4±15.6个月中,计算机断层扫描用于评估3个水平的主动脉最大直径和真假管腔直径的术后变化,技术成功率为100%。急性组住院和30天死亡率为3.3%,慢性组为0。 I型,II型和逆行A型解剖的放电后发生率分别为6.7%,5.2%和3.4%(急性)和0%,4.0%和4.0%(慢性)。在急性和慢性组的所有三个水平中,最大主动脉直径均保持稳定。在急性和慢性组中,3年累积的全因死亡率自由度相似(89.5%比95.5%,P = 308)。在急性和慢性组中,主动脉相关死亡率的累积自由度也没有显着差异(92.8%vs 95.2%,P = .531)。在胸主动脉中,TEVAR治疗导致真管腔(TL)直径显着增加,假管腔(FL)减少。但是,在腹主动脉中,TEVAR并未导致TL和FL直径发生明显变化。完全血栓形成的胸腔假性腔率要好于腹部假腔。TEVAR是一种复杂的急,慢性B型清扫术,早期和中期死亡率和发病率均较低,是一种安全有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号